Clinical trial
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage…
NCT00281957 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00281957 |
|---|---|
| Title | Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery |
| Official title | A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) With Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Drug |
| Interventions | sorafenib tosylate, tipifarnib, temsirolimus |
| Enrollment | 109 |
| Start date | Aug 1, 2007 |
| Primary completion | Dec 1, 2010 |
| Completion | Jan 1, 2011 |
| First posted | Jan 25, 2006 |
| Last update posted | May 20, 2014 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: